Day One Biopharmaceuticals Inc Share Price & Technical Analysis
DAWN · $21.53
Healthcare / Biotechnology
$21.53
Day One Biopharmaceuticals, Inc., a commercial-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for childhood and adult diseases with equal intensity in the United States. The company's lead product candidate is tovorafenib, an oral and brain-penetrant type II rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinic…
Price chart
Seasonality
May has 1 positive and 3 negative years (last 5 years shown)
125% return in 2026, -21% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 20% | -5% | 110% | 0% | – | – | – | – | – | – | – | – | 125% |
| 25 | -4% | -25% | -13% | -1% | -18% | 2% | 3% | 12% | -7% | 4% | 28% | -1% | -20% |
| 24 | 5% | 9% | -2% | 4% | -22% | 1% | 4% | -9% | 1% | 6% | -5% | -9% | -17% |
| 23 | 2% | -15% | -28% | -7% | 6% | -11% | 11% | 2% | -9% | -3% | -2% | 26% | -26% |
| 22 | -12% | -7% | -27% | -13% | -30% | 189% | -4% | 37% | -15% | 4% | 3% | -2% | 123% |
Monthly return % by calendar month · historical pattern, not a forecast
Neutral · Strong · Overbought
Day One Biopharmaceuticals, Inc., a commercial-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for childhood and adult diseases with equal intensity in the United States. The company's lead product candidate is tovorafenib, an oral and brain-penetrant type II rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed or refractory low-grade glioma; and Ipsen, a frontline raf-altered pLGG which is in Phase III clinical trial stage. It is also developing DAY301, a PTK7 targeted ADC composed of a novel humanized anti-PTK7 immunoglobulin G1 monoclonal antibody conjugated with a topoisomerase I inhibitor via a highly stable and hydrophilic modified valine-alanine (VA) cleavable linker for the treatment of patients with advanced solid tumors; and Emi-Le, an antibody-drug conjugate that targets B7- H4 conjugated to an auristatin anti-tubulin payload as a component of a proprietary linker-payload platform developed by Mersana Therapeutics that is in Phase 1 clinicla trial for the treatment of breast cancer, ovarian cancer, endometrial cancer, and adenoid cystic carcinoma (ACC). Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California. As of April 22, 2026, Day One Biopharmaceuticals, Inc. operates as a subsidiary of Servier Pharmaceuticals LLC.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$2.22B
P/E ratio
—
52W high
$21.53
52W low
$5.63
Volume
26,71,205
Beta
-1.75
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Day One Biopharmaceuticals Inc share price today?
- Day One Biopharmaceuticals Inc (DAWN) last traded around $21.53 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does DAWN have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for DAWN. Download the app for real-time alerts.
- How can I analyze Day One Biopharmaceuticals Inc stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.